Jason T Lee1,2, Hanwen Zhang2, Maxim A Moroz2, Yury Likar2, Larissa Shenker2, Nikita Sumzin2, Jose Lobo2, Juan Zurita2, Jeffrey Collins1, R Michael van Dam1, Vladimir Ponomarev3,4,5. 1. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, California NanoSystems Institute Rm 2151, 570 Westwood Plaza, Los Angeles, CA, 90095, USA. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. ponomarv@mskcc.org. 4. Sloan Kettering Institute, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. ponomarv@mskcc.org. 5. Molecular Imaging Laboratory, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. ponomarv@mskcc.org.
Abstract
PURPOSE: Radionuclide-based reporter gene imaging has the sensitivity to monitor gene- and cell-based therapies in human subjects. Potential immunogenicity of current viral transgenes warrants development of human-based reporter systems. We compared human nucleoside kinase reporters to a panel of nucleoside analogs of FEAU, FMAU, and FIAU, including the first in vivo assessment of L-[18F]FEAU. PROCEDURES: Human isogenic U87 cell lines were transduced to express different human reporter genes including dCK-R104M/D133A (dCKDM), dCK-R104Q/D133N (dCKep16A), dCK-A100V/R104M/D133A (dCK3M), and TK2-N93D/L109F (TK2DM), and wild-type dCK (dCK) and herpes simplex virus type-1 (HSVTK) reporter gene as references. In vitro cell uptake assays were performed with [18F]FEAU, L-[18F]FEAU, [14C]FMAU, L-[18F]FMAU, and [124I]FIAU. Micro-positron emission tomography/X-ray computed tomography imaging of xenograft-bearing nu/nu mice was conducted with [18F]FEAU, L-[18F]FEAU, L-[18F]FMAU, and [124I]FIAU on consecutive days. A cell viability assay was also performed to assess sensitivities to gemcitabine and bromovinyldeoxyuridine (BVdU). RESULTS: In vitro, dCKep16A and dCKDM with [18F]FEAU exhibited the highest sensitivity and selectivity of the human reporters, second only to HSVTK/[18F]FEAU. L-[18F]FEAU biodistribution in mice was on par with [18F]FEAU and L-[18F]FMAU. L-[18F]FMAU uptake in isogenic xenografts was highest for all human reporter genes. However, [18F]FEAU was the most selective of the short half-life reporter probes due to its minimal recognition by human dCK and relative sensitivity, whereas [124I]FIAU permitted imaging at a later time point, improving signal-to-background ratio. Of the human reporter genes, dCKep16A consistently outperformed the other tested reporters. Reporter genes of interest increased potency to the nucleoside analog prodrugs gemcitabine and BVdU. CONCLUSIONS: We demonstrate that human nucleoside kinase reporter systems vary significantly in their sensitivity and selectivity for in vivo imaging. The sufficiently high signal-to-background ratios and enhanced suicide gene potential support clinical translation.
PURPOSE: Radionuclide-based reporter gene imaging has the sensitivity to monitor gene- and cell-based therapies in human subjects. Potential immunogenicity of current viral transgenes warrants development of human-based reporter systems. We compared humannucleoside kinase reporters to a panel of nucleoside analogs of FEAU, FMAU, and FIAU, including the first in vivo assessment of L-[18F]FEAU. PROCEDURES: Human isogenic U87 celllines were transduced to express different human reporter genes including dCK-R104M/D133A (dCKDM), dCK-R104Q/D133N (dCKep16A), dCK-A100V/R104M/D133A (dCK3M), and TK2-N93D/L109F (TK2DM), and wild-type dCK (dCK) and herpes simplex virus type-1 (HSVTK) reporter gene as references. In vitro cell uptake assays were performed with [18F]FEAU, L-[18F]FEAU, [14C]FMAU, L-[18F]FMAU, and [124I]FIAU. Micro-positron emission tomography/X-ray computed tomography imaging of xenograft-bearing nu/nu mice was conducted with [18F]FEAU, L-[18F]FEAU, L-[18F]FMAU, and [124I]FIAU on consecutive days. A cell viability assay was also performed to assess sensitivities to gemcitabine and bromovinyldeoxyuridine (BVdU). RESULTS: In vitro, dCKep16A and dCKDM with [18F]FEAU exhibited the highest sensitivity and selectivity of the human reporters, second only to HSVTK/[18F]FEAU. L-[18F]FEAU biodistribution in mice was on par with [18F]FEAU and L-[18F]FMAU. L-[18F]FMAU uptake in isogenic xenografts was highest for allhuman reporter genes. However, [18F]FEAU was the most selective of the short half-life reporter probes due to its minimal recognition by humandCK and relative sensitivity, whereas [124I]FIAU permitted imaging at a later time point, improving signal-to-background ratio. Of the human reporter genes, dCKep16A consistently outperformed the other tested reporters. Reporter genes of interest increased potency to the nucleoside analog prodrugs gemcitabine and BVdU. CONCLUSIONS: We demonstrate that humannucleoside kinase reporter systems vary significantly in their sensitivity and selectivity for in vivo imaging. The sufficiently high signal-to-background ratios and enhanced suicide gene potential support clinical translation.
Entities:
Keywords:
Deoxycytidine kinase; Gene and cell therapy; Human reporter gene imaging; Immunotherapy; L-[18F]FEAU; L-[18F]FMAU; Thymidine kinase; [124I]FIAU; [14C]FMAU; [18F]FEAU
Authors: Jose S Gil; Hidevaldo B Machado; Dean O Campbell; Melissa McCracken; Caius Radu; Owen N Witte; Harvey R Herschman Journal: Mol Imaging Biol Date: 2013-06 Impact factor: 3.488
Authors: Yury Likar; Juan Zurita; Konstantin Dobrenkov; Larissa Shenker; Shangde Cai; Anton Neschadim; Jeffrey A Medin; Michel Sadelain; Hedvig Hricak; Vladimir Ponomarev Journal: J Nucl Med Date: 2010-09 Impact factor: 10.057
Authors: V Ponomarev; M Doubrovin; C Lyddane; T Beresten; J Balatoni; W Bornman; R Finn; T Akhurst; S Larson; R Blasberg; M Sadelain; J G Tjuvajev Journal: Neoplasia Date: 2001 Nov-Dec Impact factor: 5.715
Authors: Tadashi Miyagawa; George Gogiberidze; Inna Serganova; Shangde Cai; Julius A Balatoni; Howard T Thaler; Lyudmila Ageyeva; Nagavarakishore Pillarsetty; Ronald D Finn; Ronald G Blasberg Journal: J Nucl Med Date: 2008-03-14 Impact factor: 10.057
Authors: Ryuichi Nishii; Andrei Y Volgin; Osama Mawlawi; Uday Mukhopadhyay; Ashutosh Pal; William Bornmann; Juri G Gelovani; Mian M Alauddin Journal: Eur J Nucl Med Mol Imaging Date: 2007-12-04 Impact factor: 9.236
Authors: Matthew S Skovgard; Hocine R Hocine; Jasmeen K Saini; Maxim Moroz; Rebecca Y Bellis; Srijita Banerjee; Aurore Morello; Vladimir Ponomarev; Jonathan Villena-Vargas; Prasad S Adusumilli Journal: Mol Ther Oncolytics Date: 2021-06-12 Impact factor: 6.311
Authors: David Akhavan; Darya Alizadeh; Dongrui Wang; Michael R Weist; Jennifer K Shepphird; Christine E Brown Journal: Immunol Rev Date: 2019-07 Impact factor: 12.988
Authors: Massis Krekorian; Gilbert O Fruhwirth; Mangala Srinivas; Carl G Figdor; Sandra Heskamp; Timothy H Witney; Erik H J G Aarntzen Journal: Theranostics Date: 2019-10-16 Impact factor: 11.556